Importantly, the effects of CDK4/6 inhibition in the NSCLC cell lines utilized here were reflected in the genetically-engineered mouse model of Kras-mutant lung adenocarcinoma. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.